英国公司Microbiotica开始使用活肠道细菌进行新的性结肠炎治疗试验. UK firm Microbiotica starts trial for new ulcerative colitis treatment using live gut bacteria.

英国一家生物药剂公司,微生素公司,已开始在其第1b阶段试验MB310时对病人施药,该试验是口服胶囊,旨在治疗阴性结肠炎(UC)。 Microbiotica, a UK biopharma company, has begun dosing patients in its Phase 1b trial for MB310, an oral capsule aimed at treating ulcerative colitis (UC). 这次国际试验的目的是在五个国家招募多达30名病人,它将评估含有八种活菌菌株的MB310的安全和初步功效。 The international trial, set to recruit up to 30 patients across five countries, will assess the safety and initial efficacy of MB310, which contains eight live gut bacteria strains. 预计到2025年底将获得初步数据。 Initial data is expected by the end of 2025.